Company profile: Inspirna
1.1 - Company Overview
Company description
- Provider of oncology therapeutics and discovery technology, including ompenaclid (RGX-202), an oral SLC6A8 inhibitor in Phase 2 for advanced RAS-mutant colorectal cancer; abequolixron (RGX-104), an oral LXR/APOE activator in Phase 1b/2 for advanced non-small cell lung and endometrial cancer; the RNA-DRIVEr platform for novel cancer drivers; and RGX-019, a preclinical MERTK-targeting ADC; with active clinical trial recruitment.
Products and services
- Abequolixron (RGX-104): An oral small molecule activator of LXR/APOE that blocks tumor angiogenesis and suppresses myeloid cells, enhancing anti-tumor immunity, in Phase 1b/2 for advanced NSCLC and endometrial cancer
- Ompenaclid (RGX-202): An oral small molecule inhibitor of SLC6A8 that induces apoptosis in colorectal cancer cells, currently in Phase 2 trials for advanced colorectal cancer with RAS mutations
- RNA-DRIVEr Discovery Platform: A proprietary discovery platform that enables identification of previously unknown cancer drivers amenable to targeting by small molecules and biologics, accelerating development of therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Inspirna
Oxford Biomedica
HQ: United Kingdom
Website
- Description: Provider of gene and cell therapy solutions, offering lentiviral LentiVector and AAV platforms for development and manufacturing of gene therapies, plus CDMO services for viral vectors including tech transferred-in execution of client-defined methods, process development, GMP manufacturing, and regulatory support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Biomedica company profile →
Avivia
HQ: The Netherlands
Website
- Description: Provider of pharmaceutical CRO services, including analytical testing, drug formulation, generic drugs, repurposing, and troubleshooting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avivia company profile →
Lilly
HQ: United States
Website
- Description: Provider of medicines for diabetes, cancer, immunology, and other major health areas, including insulin products with affordability initiatives ($35 or less/month); Efsitora for type 2 diabetes via autoinjector; EBGLYSS for moderate-to-severe atopic dermatitis; Jaypirca for relapsed/refractory MCL and CLL/SLL; Zepbound (tirzepatide) for obesity; Verzenio for HR+, HER2- early breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lilly company profile →
Roquefort Therapeutics
HQ: United Kingdom
Website
- Description: Provider of pre-clinical anti-cancer therapeutics, including Midkine-targeting antibodies; antisense oligonucleotides to reduce Midkine in cancer cells; gene-editing RNA and mRNA therapies for solid tumors; STAT-6 siRNA therapeutics; and MK cell therapy with direct and NK cell-mediated action, advancing candidates toward clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Roquefort Therapeutics company profile →
Confo Therapeutics
HQ: Belgium
Website
- Description: Provider of GPCR-focused drug discovery solutions leveraging proprietary Confo® Technology and conformationally selective VHH ConfoBodies® to stabilize GPCRs in active, disease-relevant states. Offerings include ConfoScreen®, ConfoSensor®, and ConfoStructure™ for screening, biosensing, and structure-based design, and MegaBody™ for high-resolution cryo-EM, enabling novel medicine discovery and internal programs addressing unmet medical need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Confo Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Inspirna
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Inspirna
2.2 - Growth funds investing in similar companies to Inspirna
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Inspirna
4.2 - Public trading comparable groups for Inspirna
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →